Cerebrospinal fluid markers in MS patients and their healthy siblings - PubMed
Cerebrospinal fluid markers in MS patients and their healthy siblings
S Haghighi et al. Acta Neurol Scand. 2004 Feb.
Abstract
In a previous study we found that nine of 47 siblings to multiple sclerosis (MS) patients with a normal neurological examination carry an intrathecal oligoclonal immunopathy with limited specificity, a condition we termed MS immunopathic trait. The purpose of this study is to further characterize the MS immunopathic trait phenotype. We found that the neurofilament light protein (NFL) and glial fibrillary acidic protein (GFAp) concentrations were increased in the group of patients with clinically definite MS (n = 47) in latent or slowly progressive phases. There was no increase in GFAp and NFL in cerebrospinal fluid in the healthy siblings of MS patients (n = 47), nor in the subgroup of these siblings with MS immunopathic trait (n = 9) compared with a group of healthy control subjects (n = 50). Thus, there was no indication of presymptomatic CNS parenchymal involvement in MS immunopathic trait.
Similar articles
-
Haghighi S, Frisén L, Odén A, Andersen O. Haghighi S, et al. Acta Neurol Scand. 2003 Nov;108(5):319-22. doi: 10.1034/j.1600-0404.2003.00130.x. Acta Neurol Scand. 2003. PMID: 14616300
-
Glial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosis.
Axelsson M, Malmeström C, Nilsson S, Haghighi S, Rosengren L, Lycke J. Axelsson M, et al. J Neurol. 2011 May;258(5):882-8. doi: 10.1007/s00415-010-5863-2. Epub 2011 Jan 1. J Neurol. 2011. PMID: 21197541
-
Neurofilament and glial fibrillary acidic protein in multiple sclerosis.
Norgren N, Sundström P, Svenningsson A, Rosengren L, Stigbrand T, Gunnarsson M. Norgren N, et al. Neurology. 2004 Nov 9;63(9):1586-90. doi: 10.1212/01.wnl.0000142988.49341.d1. Neurology. 2004. PMID: 15534240
-
Can CSF biomarkers predict future MS disease activity and severity?
Magliozzi R, Cross AH. Magliozzi R, et al. Mult Scler. 2020 Apr;26(5):582-590. doi: 10.1177/1352458519871818. Epub 2020 Jan 22. Mult Scler. 2020. PMID: 31965889 Review.
-
Emerging imaging and liquid biomarkers in multiple sclerosis.
Gill AJ, Schorr EM, Gadani SP, Calabresi PA. Gill AJ, et al. Eur J Immunol. 2023 Aug;53(8):e2250228. doi: 10.1002/eji.202250228. Epub 2023 May 28. Eur J Immunol. 2023. PMID: 37194443 Free PMC article. Review.
Cited by
-
Alirezaei Z, Pourhanifeh MH, Borran S, Nejati M, Mirzaei H, Hamblin MR. Alirezaei Z, et al. Mol Neurobiol. 2020 Jan;57(1):469-491. doi: 10.1007/s12035-019-01698-3. Epub 2019 Aug 5. Mol Neurobiol. 2020. PMID: 31385229 Free PMC article. Review.
-
Serum-Based Biomarkers in Neurodegeneration and Multiple Sclerosis.
LoPresti P. LoPresti P. Biomedicines. 2022 May 6;10(5):1077. doi: 10.3390/biomedicines10051077. Biomedicines. 2022. PMID: 35625814 Free PMC article. Review.
-
Biernacki T, Kokas Z, Sandi D, Füvesi J, Fricska-Nagy Z, Faragó P, Kincses TZ, Klivényi P, Bencsik K, Vécsei L. Biernacki T, et al. Int J Mol Sci. 2022 Mar 21;23(6):3383. doi: 10.3390/ijms23063383. Int J Mol Sci. 2022. PMID: 35328802 Free PMC article. Review.
-
Neurofilament light chain as a biological marker for multiple sclerosis: a meta-analysis study.
Cai L, Huang J. Cai L, et al. Neuropsychiatr Dis Treat. 2018 Sep 3;14:2241-2254. doi: 10.2147/NDT.S173280. eCollection 2018. Neuropsychiatr Dis Treat. 2018. PMID: 30214214 Free PMC article. Review.
-
Neurofilament light chain as a biomarker for diagnosis of multiple sclerosis.
Kouchaki E, Dashti F, Mirazimi SMA, Alirezaei Z, Jafari SH, Hamblin MR, Mirzaei H. Kouchaki E, et al. EXCLI J. 2021 Aug 16;20:1308-1325. doi: 10.17179/excli2021-3973. eCollection 2021. EXCLI J. 2021. PMID: 34602928 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous